# A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

> **NCT01101191** · PHASE1 · COMPLETED · sponsor: **Purdue Pharma LP** · enrollment: 84 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Reformulated OXY (oxycodone HCl)
- **DRUG:** Original OxyContin® (OXY) (oxycodone HCl)

## Key facts

- **NCT ID:** NCT01101191
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2007-10
- **Final completion:** 2008-01
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2010-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01101191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01101191, "A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01101191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*